Lipocine Inc. (LPCN)
Market Cap | 15.42M |
Revenue (ttm) | 54,990 |
Net Income (ttm) | -12.06M |
Shares Out | 5.32M |
EPS (ttm) | -2.38 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 37,701 |
Open | 3.01 |
Previous Close | 2.98 |
Day's Range | 2.80 - 3.15 |
52-Week Range | 2.80 - 10.34 |
Beta | 0.97 |
Analysts | Buy |
Price Target | 33.00 (+1,037.93%) |
Earnings Date | Nov 8, 2023 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also... [Read more]
Financial Performance
In 2022, Lipocine's revenue was $500,000, a decrease of -96.90% compared to the previous year's $16.14 million. Losses were -$10.76 million, 1595.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LPCN stock is "Buy" and the 12-month stock price forecast is $33.0.
News

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Pa...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results f...

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P 1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) More patients on LPCN ...

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platfo...

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023 /PRNewswire/ -- Li...

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establish efficacy for postpartum depression (PPD) and support NDA submission LPCN 1154 t...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platfor...

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 SALT LAKE CITY , April 3, 2023 /PRNewswire/...

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock
SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of...

Lipocine Announces Financial Results for the Year Ended December 31, 2022
SALT LAKE CITY , March 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary pla...

Lipocine to Present at Biotech Showcase
Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Jan. 5, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on...

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY , Dec. 19, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Cent...

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platf...

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiat...

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
SALT LAKE CITY , Oct. 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products throu...

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
SALT LAKE CITY , Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products thro...

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders
Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial focus on oral delivery of neu...

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
SALT LAKE CITY , Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through effecti...

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)
FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine has demonstrated that the brexanolone exposure...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") ...

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY, July 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative produ...

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
SALT LAKE CITY , June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Paten...

LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented ...

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Observed liver histology improveme...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today annou...